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p21-activated kinase 6 (PAK6) is a member of the PAK family of serine/threonine kinases that are known 
effectors of Rho GTPases Cdc42 and Rac. PAKs regulate a large number of complex cellular mechanisms, 
including cell motility, morphology, and tumor development. PAK6, initially cloned as an interacting 
partner of the androgen receptor (AR), is associated with an array of cellular processes implicated in 
tumor progression. However, the full biological implications of PAK6 activity during cancer remain 
poorly understood. In this review, we assess our current understanding of the physiological roles of 
classical PAK6 functionality in mammals, in addition to its emerging role in tumorigenesis. 
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INTRODUCTION
PAKs were first discovered through the design 
of novel antifungal agents by Manser and colleagues 
(Manser et al., 1994). In the ensuing decades, PAKs 
biology has attracted significant attention. PAKs are 
regarded as oncogenes that stimulate cancer progression 
through a plethora of cell-based strategies, including 
promoting cell survival, proteolytic degradation of the 
extracellular matrix, cytoskeletal remodeling to create 
motor structures, the acceleration of angiogenesis, and 
the phosphorylation of effector substrates (Molli et al., 
2009). Structurally, PAKs are characterized by their 
N-terminal Cdc42/Rac interaction binding domain (CRIB) 
and conserved C-terminal kinase domain (Kumar et al., 
2017). To date, six members of the PAK family have been 
discovered which have been divided into two classes: 
Group I (PAK1-3) and Group II (PAK4-6), based on the 
sequence and functional homology (Radu et al., 2013). 
Group II members lack obvious autoinhibitory domains 
which are present in Group I (Radu et al., 2013). PAK6 is 
less well characterized than the other members of Group 
II PAKs, and studies on PAK6 have mainly focused on its 
role as an interacting partner of AR in prostate cancer cells, 
shown to be independent of Rho GTPases (Schrantz et al., 
2004). During recent years, it has been shown that PAK6 
is either deregulated or hyper-activated in a large number 
of human cancers (Kumar et al., 2017; Gao et al., 2013). 
Furthermore, PAK6 has been shown to be essential for 
many fundamental cellular processes typically deregulated 
in cancer, including cell migration, differentiation, and 
survival (Jaffer, Chernoff, 2002; Field, Manser, 2012). 
Given the aforementioned considerations, there is urgent 
need to decipher the mechanisms of PAK6 activation 
during human disease, particularly in the setting of cancer 
progression. 
STRUCTURE AND EXPRESSION OF PAK6
PAK6 is located on chromosome 15q15 and is a 
681 amino acid protein with a molecular mass of 75 kDa 
(Yang et al., 2001). The PAK6 gene is ~38 kb in length and 
comprises 16 exons, including 8 for 5’-UTRs, producing 
17 transcripts (Lee et al., 2002). Like other members of 
the PAK family, PAK6 contains a conserved N-terminal 
CRIB and a C-terminal kinase catalytic domain. The 
N-terminus of PAK6 is similar to the CRIB domains of 
the previously characterized PAKs and contains six of the 
eight common CRIB domain residues (Wells, Jones, 2010; 
Hofmann, Shepelev, Chernoff, 2004; Ha et al., 2012). 
The C-terminal of PAK6 has more than 50% sequence 
similarity with PAK1-3, and high homology to PAK4 
(80% homology), indicating alternative mechanisms of 
kinase regulation (Arias-Romero, Chernoff, 2008). PAK4, 
the most extensively studied Group II PAKs member, 
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is highly expressed in the colon, testes and prostate of 
humans (Jaffer, Chernoff, 2002). PAK6 is highly expressed 
in the brain and testes, and expressed to low levels in 
prostate, breast, thyroid, kidney, and placenta. There is 
little detectable PAK6 expression in the ovaries, peripheral 
blood leukocytes, lymph nodes, uterus, spleen, intestine, 
liver, lung, thymus, or bone marrow (Yang et al., 2001).
BIOLOGICAL FUNCTION OF PAK6
PAK6 modulates a plethora of biological activities, 
including cell proliferation, apoptosis, invasion, metastasis 
and cytoskeletal rearrangements (Eswaran et al., 2007). 
As an exemplar, PAK6 overexpression has been shown 
to drive cell–cell dissemination (Fram et al., 2014). 
Fram and colleagues demonstrated that PAK6 binds 
to cell–cell adhesions, co-localizing with E-cadherin 
and IQ motif containing GTPase activating protein 1 
(IQGAP1) at these regions (Fram et al., 2014). The 
interplay between the C-terminal kinase catalytic domain 
of PAK6 and the N-terminus of IQGAP1 plays a vital role 
in the formation of cell–cell junctions. The N-terminus 
of PAK6 is necessary and sufficient for its targeting to 
cell-cell adhesions, suggesting its catalytic activity is 
not required (Morse et al., 2016). Additionally, PAK6 
localization at cell-cell adhesions requires Cdc42, an 
evolutionarily conserved polarity protein that acts as an 
upstream activator of PAKs (Takahashi, Pryciak, 2007; 
Su et al., 2005; Baskaran et al., 2012). PAK6 promotes 
cell-cell dissociation through its ability to target cell-cell 
adhesion, as determined by epithelial cell colony escape 
assays, the key progress in epithelial mesenchymal 
transition (EMT) (Morse et al., 2016). Investigation of the 
molecular interactions leading to junctional dissociation 
and the identification of proteins involved in this process 
will be beneficial to our broader understanding of cancer 
progression.
PAK6 is highly expressed in brain tissue, particularly 
the cortical structure, suggesting a crucial role in the central 
nervous system (CNS) (Minden, 2012; Civiero et al., 
2015). Although its precise function in the CNS remains 
unclear, several recent studies suggest a role for PAK6 
during cognitive behavior. In learning and memory 
behavioral tests, PAK5/PAK6 double-knockout mice show 
slight learning and memory deficits and locomotor changes 
compared with wild-type controls (Nekrasova et al., 
2008). Whilst PAK6 knockout mice were similar to wild 
type mice, PAK5 knockout mice displayed a modest loss 
in learning ability and memory function, which was less 
pronounced than the PAK5/PAK6 double knockout. This 
suggests at least a partial overlap between PAK6 and 
PAK5 CNS functions. PAK5/PAK6 double-knockout mice 
also displayed alterations in neuronal morphological and 
synaptic contact arrangements that likely contribute to 
the defects. This highlights the interplay between Group 
II PAKs and their contribution to neuronal processes 
(Skoulakis et al., 2013). 
A potential candidate that contributes to these 
processes is LIM kinase (LIMK), a substrate for several 
PAKs, including PAK6 (Cai et al., 2015). Defects in 
LIMK1 are associated with Williams syndrome, a 
neurodevelopmental disorder that causes learning and 
behavior disorders (Matsumoto, Kitani, Kalinec, 2011). 
In addition, PAK6 plays an essential role in weight gain 
unrelated to caloric intake and exercise (Furnari et al., 
2014; Kreis, Barnier, 2009). PAK6 also decreases AR 
and estrogen receptor (ER) transcriptional expression. 
AR participates in body weight determination and 
challenge, providing further evidence of a role for PAK6 
during weight gain, independent of exercise and calorie 
intake (Lee et al., 2002; Narayanan, Coss, Dalton, 
2017). More importantly, PAK6 also participates in CNS 
pathophysiology following traumatic brain injury (TBI), 
the dominant cause of disability and death globally. TBI 
leads to secondary tissue loss and glial scar formation 
and impairs the regeneration associated with functional 
disabilities (Zhao et al., 2011). Likewise, PAK6 expression 
is markedly increased in astrocytes and neurons and is 
associated with astrocyte proliferation following spinal 
cord injury (SCI) in adult rats (Chen, Zhao, Shen, 2011). 
The known activation of PAK6 by the MAP kinase 
kinase 6 (MKK6)/p38 pathway further implicates its 
involvement in stress-related signaling (Kaur et al., 2004). 
Furthermore, proliferating cell nuclear antigen (PCNA) is 
a cyclin involved in mitotic G1/S progression and that is 
up-regulated in astrocytes after SCI (Chen, Zhao, Shen, 
2011). PAK6 induction in astrocytes accompanies this 
upregulation (Chen, Zhao, Shen, 2011). Further studies 
investigating the function of PAK6 during CNS injury and 
repair may reveal novel molecular pathways that can be 
manipulated during the treatment of CNS trauma. 
THE ROLE OF PAK6 IN CANCER
Cancer is a progressive disease caused by genomic 
instability, resulting in chromosome translocations 
(Hofmann, Shepelev, Chernoff, 2004). Considering the 
highly unpredictable and complex natural history of 
cancer, it is of the utmost important to explore molecular 
pathways, identify prognostic factors, and develop more 
sensitive and accurate integrated prognostic models 
(Torre et al., 2015). Aberrant expression of PAK6 is 
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observed in several cancers, with its contribution to 
prostate cancer development and progression following 
androgen deprivation therapy well defined.
Prostate cancer
Prostate cancer is one of the most common causes 
of cancer deaths and represents one of the most dominant 
cancers in males in the United States and Western Europe, 
largely due to the limitations of the current treatment 
modalities, particularly following metastasis (Liu et al., 
2013b). The AR is a member of the steroid hormone 
receptor of the larger nuclear receptor family and plays 
an essential role in the development of prostate cancer 
(Narayanan, Coss, Dalton, 2017). Tong and colleagues 
revealed that PAK6 could inhibit prostate cancer growth 
in vivo by promoting AR ubiquitin-mediated degradation 
through AR and Mdm2 phosphorylation (Liu et al., 
2013a). This result is surprising since PAK6 is highly 
expressed in metastatic and primary cancers. In prostate 
cancer cell lines, PAK6 expression is significantly higher 
in malignant prostate tissue and correlates with tumor 
grade (Liu et al., 2013b). Similarly, increased PAK6 
staining significantly correlates with a higher Gleason 
score (Kaur et al., 2008). One interpretation of these 
findings is that the expression of PAK6 increases to 
inhibit excessive AR expression and tumor aggressiveness 
(Liu et al., 2013a). Indeed, increased nuclear translocation 
of AR correlates with high malignancy in prostate cancer 
(Liu et al., 2013a). The stress-induced activation of PAK6 
in response to enhanced AR activity may explain its over-
expression in prostate cancer. PAK6 may further influence 
carcinogenesis and prostate cancer progression through 
diverse signal transduction pathways including protein 
phosphatase 1B (PP1B) and IQGAP1, both of which are 
PAK6 interacting partners (Kaur et al., 2008; Fram et al., 
2014). IQGAP1 plays a critical role in cell adhesion and 
coordinates multiple signaling pathways in many cell 
types (Choi, Anderson, 2016; Abel et al., 2015). 
Various microRNAs (miRs) are involved in prostate 
cancer development and progression (Farazi et al., 2013). 
Previous studies have demonstrated that PAK6 is directly 
targeted by miR-328 (Liu et al., 2015a) and a miR-23a-
PAK6-LIMK1 regulatory pathway has been shown to 
promote prostate cancer metastasis (Cai et al., 2015). 
PAK6 is negatively correlated to miR-23a in prostate 
cancer tissue (Cai et al., 2015). MiR-23a reduces PAK6 
expression by directly binding to complementary sites in 
the 3′-UTR of PAK6 (Cai et al., 2015). The expression of 
miR-23a suppresses LIMK and cofilin phosphorylation, 
which in turn inhibits the formation of actin filaments 
and stress fibers required for cell invasion and motility 
(Cai et al., 2015). PAK6 therefore represents a valuable 
therapeutic target for prostate cancer treatment. 
PAK6 is implicated in mediating the response to 
radiotherapy and chemotherapy during prostate cancer 
treatment (Zhang et al., 2010). PAK6 silencing enhances 
the chemosensitivity of docetaxel, but the molecular basis 
for this remains unclear. Min and coworkers found that 
PAK6 mediates the resistance of prostate cancer cells 
to radiation therapy (Zhang et al., 2010), with PAK6 
inhibition decreasing the levels of radiation-induced 
apoptosis in prostate cancer cells (Wen et al., 2009). It 
is well-known that local and systemic recurrence after 
radiotherapy (a curative treatment for clinically localized 
prostate cancer) is high, suggesting that drug resistance 
is a common event. The underlying mechanisms by 
which PAK6 mediates radiation therapy responses 
involves changes in cell cycle distribution, altered BAD 
phosphorylation, and impaired DNA double-strand break 
repair (Zhang et al., 2010). In addition, PAK6 expression 
is significantly associated with Proteasome beta-4 subunit 
(PSMB4) (Zapatero et al., 2014). The over-expression 
of PSMB4 and its role in proteasome mediated survival 
inhibition has been demonstrated in several metastatic and 
primary solid tumors (Liu et al., 2016). Taken together, 
these studies highlight PAK6 as a viable target to improve 
the effectiveness of radiotherapy during prostate cancer 
treatment. 
Hepatocellular carcinoma
Although a variety of prognostic indicators of 
hepatocellular carcinoma (HCC) (including osteopontin, 
transforming growth factor and vascular endothelial 
growth factor) have originated from a large number of 
clinical and basic research efforts, effective treatment 
modalities remain rare, and liver transplantation is the 
primary therapeutic strategy for early HCC patients 
(Chen et al., 2014). New strategies to improve HCC 
treatment are urgently required. PAK6 expression 
decreases during HCC development with its inhibition 
associated with a poor clinical outcome (Liu et al., 
2015b). Furthermore, under the epigenetic regulation 
of multiple inhibitory complex 2 (PRC2), PAK6 acts as 
a tumor suppressor during HCC development, which is 
dependent on its nuclear translocation and kinase activity 
(Liu et al., 2015b). PRC2 has both oncogenic and tumor 
suppressor functions and catalyzes the trimethylation of 
histone H3 lysine 27 (H3K27), an inhibitory chromatin 
marker that correlates with gene silencing (Holoch, 
Margueron, 2017). EZH2, the catalytic subunit of 
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PRC2, is negatively associated with PAK6 in HCC, 
providing further evidence of its tumor suppressive role 
during hepatocarcinogenesis (Jain, Di Croce, 2016; 
Liu et al., 2015b). These findings demonstrate that PAK6 
suppression contributes to HCC (Figure 1). In contrast, 
retrospective studies suggest that PAK6 is markedly 
elevated in HCC specimens and positively associated 
with HCC cell proliferation (Chen et al., 2014). High 
expression of PAK6 also correlates with the Edmondsone 
Steiner classification, poor prognosis and the number of 
tumor nodules (Chen et al., 2014). However, the detailed 
molecular mechanisms of how PAK6 over-expression 
contributes to HCC remains poorly understood. Given 
the retrospective nature of the study and the limitations 
of investigating patients in a single institution of a single 
histological type, these conclusions require validation in 
large-scale, multi-agency and prospective studies. Further 
studies into the relationship of PAK6 and PRC2 may fully 
reveal its role during HCC development. Interestingly, 
the contradictory findings regarding the role of PAK6 in 
cancer have similarly been reported in prostate cancer, 
and may thus be a consequence of the intricate molecular 
functions of PAK6. DNA methylation analysis has also 
demonstrated hypermethylation in the PAK6 promoter 
in prostate cancer cells, which is associated with gene 
transcriptional silencing. These genes are connected 
to the inhibition of tumor progression and are known 
tumor suppressors (Lee et al., 2010). It will be interesting 
to determine whether PAK6 has both oncogenic and 
tumor suppressive functions during the progression and 
development of cancer in future studies. 
Colon cancer
Colon cancer (CC) that is located in the sigmoid or 
descending colon is defined as left colorectal cancer (LCC), 
whilst that located in the transverse colon, ascending colon, 
and cecum is defined as right colorectal cancer (RCC) 
(Yang et al., 2017). CC is one of the leading causes of 
cancer related mortality worldwide, the median survival rate 
for patients remaining poor (Feng et al., 2017). Although 
therapeutics targeting cell signaling pathways remains a 
pillar of current cancer research, drug resistance remains a 
major obstacle (Chen, Lin, Chen, 2017). Systemic adjuvant 
chemotherapy based on 5-fluorouracil (5-FU) has been 
proposed for patients with a high recurrence risk and has 
been shown to be beneficial in many trials (Mori et al., 
2017). Chen and colleagues demonstrated that PAK6 
reduces the sensitivity of 5-FU drugs and the combination of 
PAK6 inhibition and 5-FU treatment results in a significant 
reduction in colon cancer cell survival (Chen et al., 2015). 
This suggests that PAK6 expression may provide prognostic 
value in determining optimal individualized treatment 
regimens during colon cancer diagnosis, by differentiating 
those patients predicted to respond to postoperative 
chemotherapy. Most importantly, PAK6 expression is 
upregulated in colon cancer tissue compared with normal 
colon epithelial cells (Tian et al., 2015). Studies have 
revealed that PAK6 signaling is linked to miR-429-mediated 
colon cancer cell invasion and migration (Tian et al., 
2015). miR-429 deregulation is implicated in pancreatic, 
oropharyngeal carcinoma, colon cancer and non-small cell 
lung cancer (NSCLC) (Wang et al., 2016). PAK6 expression 
is negatively regulated by miR-429 in colon cancer cells 
(Tian et al., 2015). 
It is therefore clear that PAK6 represents an 
independent prognostic factor for colon cancer patients. 
The expansion and molecular mechanisms of PAK6 
specific substrates will further our understanding of the 
role of PAK6 during tumorigenesis.
Other cancers
In contrast to PAK4, PAK6 function during tumor 
progression remains poorly characterized. However, PAK6 
has been suggested to play a crucial role in the progression 
and development of lung cancer, gastric cancer (GC) 
and clear cell renal cell carcinoma (ccRCC) (Table I). 
FIGURE 1 - The epigenetic regulation of PAK6 in HCC.
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Low levels of PAK6 have been documented to correlate 
with poor overall survival and recurrence-free survival 
in ccRCC patients following nephrectomy (Liu et al., 
2014). These findings suggest that PAK6 in ccRCC acts 
as a tumor suppressor gene and that its low expression in 
surgical tumor tissue predicts a poorer clinical outcome. 
This suggests that patients with early stage ccRCC should 
be treated under strict surveillance (Liu et al., 2014). 
PAK1 is overexpressed in RCC tissue and may represent 
a potential therapeutic target (O’Sullivan et al., 2007). In 
addition, compared to surrounding non-tumor mucosa, 
PAK6 expression is increased in GC tissue and correlates 
with poor prognosis following chemotherapy (Jiang et al., 
2017). Since chemotherapy is recommended as a standard 
postoperative treatment for advanced GC, individualizing 
patient management based on PAK6 expression may 
be beneficial (Kawai et al., 2017). Epigenetic changes 
associated with the histological features of each cancer may 
aid our understanding of the molecular context of clinical 
pathological diversity in human cancers. In addition, since 
PAK6 inhibition decreases cell proliferation, invasion and 
motility of cigarette smoke treated cells (Raja et al., 2016), 
studies investigating PAK6 as a potential therapeutic target 
for NSCLC, particularly in smokers, should be prioritized 
(Raja et al., 2016). Understanding the complexity of 
cancer relies on clarifying the basic regulatory network 
of intercellular and cellular levels and their temporal 
dimensions. Significantly, it has been reported that PAK6 
methylation acts as a marker of adenocarcinoma (ACA) 
allowing its distinction from squamous cell carcinoma 
(SCC) (Lee et al., 2010). Changes in DNA methylation 
remain one of the most common molecular alterations 
in human neoplasia which may represent an early event 
occurring during cancer development, providing a unique 
perspective as an early detection marker (Laird, 2003). 
Exploration of the detailed molecular mechanisms of 
PAK6 in various tumors and its potential clinical value is 
therefore highly encouraged.
CONCLUSIONS
Although we remain at  the early stages of 
understanding the fundamental roles of Group II PAKs, 
there is evidence that the two subgroups vary in terms 
of their substrate preferences, biochemical properties, 
and cellular and developmental functions (Dammann, 
TABLE I - Aberrant expression of PAK6 in tumors
Tumor Mechnism Potential target Effect References
Prostate cancer AR-ubiquitin-mediated 
degradation through E3 
ligase Mdm2
AR Aberrent expressed in prostate 
cancer
(Liu et al., 2013a)
miR-23a-PAK6-LIMK1 miR-23a/LIMK1 (Cai et al., 2015)
miR-328-PAK6 miR-328 (Liu et al., 2015a)
Colon cancer miR-429 Promotion of cell 
migration and invasion
(Tian et al., 2015)
Lung cancer (NSCLC) Promotion of cell 
proliferation, migration 
and invasion
(Raja et al., 2016)
HCC Aberrently expressed in HCC (Chen et al., 2014; 
Liu et al., 2015b)
Clear cell Renal cell 
carcinoma
Associated with unfavorable 
OS (P = 0.001) and RFS 
(P = 0.001)
(Liu et al., 2014)
Breast cancer Over-expressed in breast 
cancer cells
(Kaur et al., 2008)
Gastric cancer Over-expressed in gastric 
cancer
(Jiang et al., 2017)
Thyroid cancer Expressed in normal and 
malignant thyroid tissues 
(McCarty et al., 2010)
NSCLC: non-small cell lung cancer AKT: protein kinase B HCC: hepatocellular carcinoma OS: overall survival RFS: recurrence-
free survival.
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Khare, Gasche, 2014). Accumulating data also shows 
that PAK6 is aberrantly expressed in a large number of 
human diseases, including cancer (Rudolph et al., 2014). 
With regards to the function of PAK6 in cancer, we have 
a reasonable understanding of the signal-framework 
(Figure 2), but some basic problems remain unanswered. 
Whilst most PAKs are considered oncogenes, emerging 
evidence suggests that different PAKs have different or 
even opposite functions during cancer development. These 
differences may be caused by varying levels of regulation, 
including optimal phosphorylation sites, different effects 
of Cdc42 interactions, and alternative substrates, including 
AR for PAK6. Unravelling the answers to these questions 
will improve our understanding of these new kinases, 
and the signaling pathways through which they mediate 
their ultimate cellular functions. Further studies regarding 
the function of PAK6 are now warranted in a range of 
contexts to further explore its role in tumor development. 
PAK6 may emerge as one of most frequently up-regulated 
pathways in human cancer, revealing members of the PAK 
family as novel anti-cancer therapeutic targets.
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